{"id":23175,"date":"2023-04-13T14:04:45","date_gmt":"2023-04-13T12:04:45","guid":{"rendered":"https:\/\/www.anderapartners.com\/?p=23175"},"modified":"2023-04-13T14:16:02","modified_gmt":"2023-04-13T12:16:02","slug":"bioventrix-cloture-un-tour-de-financement-de-serie-a-de-485-millions-de-dollars","status":"publish","type":"post","link":"https:\/\/www.anderapartners.com\/fr\/bioventrix-cloture-un-tour-de-financement-de-serie-a-de-485-millions-de-dollars\/","title":{"rendered":"BioVentrix\u00ae cl\u00f4ture un tour de financement de s\u00e9rie A de 48,5 millions de dollars"},"content":{"rendered":"

BioVentrix, Inc.<\/strong> a annonc\u00e9 aujourd’hui la cl\u00f4ture d’un tour de financement de s\u00e9rie A de 48,5 millions de dollars. BioVentrix est une soci\u00e9t\u00e9 de dispositifs m\u00e9dicaux bas\u00e9e \u00e0 Mansfield (Massachusetts, Etats-Unis) qui d\u00e9veloppe des dispositifs th\u00e9rapeutiques peu invasifs pour traiter directement la dilatation du ventricule gauche et inverser le processus de remodelage ventriculaire gauche chez les patients souffrant d’insuffisance cardiaque congestive isch\u00e9mique.<\/p>\n

Le tour de financement a \u00e9t\u00e9 men\u00e9 par Andera Partners, acteur de premier plan du capital-risque d\u00e9di\u00e9 notamment aux sciences de la vie, au sein d\u2019un consortium d\u2019investisseurs \u00e9galement compos\u00e9 de Cormorant Asset Management, Taglich Brothers Inc., Squarepoint Capital, et Richmond Brothers, Inc. A ce titre, Rapha\u00ebl Wisniewski d’Andera Partners et Bihua Chen de Cormorant Asset Management rejoignent le Conseil d’administration de BioVentrix.<\/p>\n

Les fonds lev\u00e9s permettront \u00e0 la soci\u00e9t\u00e9 de finaliser le processus de demande d’approbation r\u00e9glementaire aux \u00c9tats-Unis pour son syst\u00e8me Revivent TC, et de financer les pr\u00e9paratifs initiaux pour le lancement commercial du produit. Ils serviront \u00e9galement \u00e0 financer le programme d\u2019autorisation temporaire d’utilisation que BioVentrix a r\u00e9cemment re\u00e7u de la Food and Drug Administration <\/em>aux \u00c9tats-Unis.<\/p>\n

Le syst\u00e8me BioVentrix Revivent TC permet une proc\u00e9dure peu invasive pour traiter la dilatation du ventricule gauche chez les patients atteints d’insuffisance cardiaque isch\u00e9mique avec fraction d’\u00e9jection r\u00e9duite (HFrEF) et souffrant d\u2019une cicatrice ventriculaire gauche \u00e9tendue, chez lesquels les traitements conventionnels n\u2019ont pas donn\u00e9 de r\u00e9sultats satisfaisants. Revivent TC repose sur l\u2019utilisation d\u2019implants de micro-ancrage myocardique pour reconstruire le ventricule gauche dilat\u00e9 et ainsi permettre un meilleur fonctionnement de la chambre de ce ventricule.<\/p>\n

Jim Dillon, Directeur G\u00e9n\u00e9ral de BioVentrix, Inc.<\/strong>, d\u00e9clare : \u00ab Notre capacit\u00e9 \u00e0 compl\u00e9ter un tour de financement aupr\u00e8s d\u2019investisseurs de premier plan et avec le soutien de nos actionnaires existants t\u00e9moigne de la qualit\u00e9 de notre \u00e9quipe et de l\u2019opportunit\u00e9 de march\u00e9 encore inexplor\u00e9e qui s’offre \u00e0 nous. Le traitement des patients atteints d’insuffisance cardiaque avanc\u00e9e par restauration ventriculaire gauche est d\u00e9sormais reconnu par la communaut\u00e9 clinique de cardiologie comme une approche dont l\u2019heure est venue. \u00bb<\/em><\/p>\n

Rapha\u00ebl Wisniewski, Associ\u00e9 d\u2019Andera Partners<\/strong>, d\u00e9clare\u00a0: \u00ab\u00a0Nous sommes heureux de mener ce tour de financement important et de soutenir cette \u00e9quipe talentueuse qui permettra \u00e0 la soci\u00e9t\u00e9 d\u2019apporter une nouvelle solution th\u00e9rapeutique aux patients atteints d\u2019insuffisance cardiaque isch\u00e9mique avanc\u00e9e\u00a0\u00bb.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"

BioVentrix, Inc. a annonc\u00e9 aujourd’hui la cl\u00f4ture d’un tour de financement de s\u00e9rie A de 48,5 millions de dollars. BioVentrix est une soci\u00e9t\u00e9 de dispositifs m\u00e9dicaux bas\u00e9e \u00e0 Mansfield (Massachusetts, Etats-Unis) qui d\u00e9veloppe des dispositifs th\u00e9rapeutiques peu invasifs pour traiter directement la dilatation du ventricule gauche et inverser le processus de remodelage ventriculaire gauche chez…<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[78],"class_list":["post-23175","post","type-post","status-publish","format-standard","hentry","category-biodiscovery"],"acf":[],"yoast_head":"\nBioVentrix\u00ae cl\u00f4ture un tour de financement de s\u00e9rie A de 48,5 millions de dollars - ANDERA PARTNERS<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.anderapartners.com\/fr\/bioventrix-cloture-un-tour-de-financement-de-serie-a-de-485-millions-de-dollars\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BioVentrix\u00ae cl\u00f4ture un tour de financement de s\u00e9rie A de 48,5 millions de dollars - ANDERA PARTNERS\" \/>\n<meta property=\"og:description\" content=\"BioVentrix, Inc. a annonc\u00e9 aujourd’hui la cl\u00f4ture d’un tour de financement de s\u00e9rie A de 48,5 millions de dollars. BioVentrix est une soci\u00e9t\u00e9 de dispositifs m\u00e9dicaux bas\u00e9e \u00e0 Mansfield (Massachusetts, Etats-Unis) qui d\u00e9veloppe des dispositifs th\u00e9rapeutiques peu invasifs pour traiter directement la dilatation du ventricule gauche et inverser le processus de remodelage ventriculaire gauche chez...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.anderapartners.com\/fr\/bioventrix-cloture-un-tour-de-financement-de-serie-a-de-485-millions-de-dollars\/\" \/>\n<meta property=\"og:site_name\" content=\"ANDERA PARTNERS\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-13T12:04:45+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-04-13T12:16:02+00:00\" \/>\n<meta name=\"author\" content=\"Nicolas Delsert\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Nicolas Delsert\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/bioventrix-cloture-un-tour-de-financement-de-serie-a-de-485-millions-de-dollars\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/bioventrix-cloture-un-tour-de-financement-de-serie-a-de-485-millions-de-dollars\/\"},\"author\":{\"name\":\"Nicolas Delsert\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c\"},\"headline\":\"BioVentrix\u00ae cl\u00f4ture un tour de financement de s\u00e9rie A de 48,5 millions de dollars\",\"datePublished\":\"2023-04-13T12:04:45+00:00\",\"dateModified\":\"2023-04-13T12:16:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/bioventrix-cloture-un-tour-de-financement-de-serie-a-de-485-millions-de-dollars\/\"},\"wordCount\":439,\"publisher\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#organization\"},\"articleSection\":[\"andera Life Sciences\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/bioventrix-cloture-un-tour-de-financement-de-serie-a-de-485-millions-de-dollars\/\",\"url\":\"https:\/\/www.anderapartners.com\/fr\/bioventrix-cloture-un-tour-de-financement-de-serie-a-de-485-millions-de-dollars\/\",\"name\":\"BioVentrix\u00ae cl\u00f4ture un tour de financement de s\u00e9rie A de 48,5 millions de dollars - ANDERA PARTNERS\",\"isPartOf\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#website\"},\"datePublished\":\"2023-04-13T12:04:45+00:00\",\"dateModified\":\"2023-04-13T12:16:02+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/bioventrix-cloture-un-tour-de-financement-de-serie-a-de-485-millions-de-dollars\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.anderapartners.com\/fr\/bioventrix-cloture-un-tour-de-financement-de-serie-a-de-485-millions-de-dollars\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/bioventrix-cloture-un-tour-de-financement-de-serie-a-de-485-millions-de-dollars\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/www.anderapartners.com\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BioVentrix\u00ae cl\u00f4ture un tour de financement de s\u00e9rie A de 48,5 millions de dollars\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#website\",\"url\":\"https:\/\/www.anderapartners.com\/fr\/\",\"name\":\"ANDERA PARTNERS\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.anderapartners.com\/fr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#organization\",\"name\":\"Andera Partners\",\"url\":\"https:\/\/www.anderapartners.com\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg\",\"contentUrl\":\"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg\",\"width\":107,\"height\":44,\"caption\":\"Andera Partners\"},\"image\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c\",\"name\":\"Nicolas Delsert\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g\",\"caption\":\"Nicolas Delsert\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BioVentrix\u00ae cl\u00f4ture un tour de financement de s\u00e9rie A de 48,5 millions de dollars - ANDERA PARTNERS","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.anderapartners.com\/fr\/bioventrix-cloture-un-tour-de-financement-de-serie-a-de-485-millions-de-dollars\/","og_locale":"fr_FR","og_type":"article","og_title":"BioVentrix\u00ae cl\u00f4ture un tour de financement de s\u00e9rie A de 48,5 millions de dollars - ANDERA PARTNERS","og_description":"BioVentrix, Inc. a annonc\u00e9 aujourd’hui la cl\u00f4ture d’un tour de financement de s\u00e9rie A de 48,5 millions de dollars. BioVentrix est une soci\u00e9t\u00e9 de dispositifs m\u00e9dicaux bas\u00e9e \u00e0 Mansfield (Massachusetts, Etats-Unis) qui d\u00e9veloppe des dispositifs th\u00e9rapeutiques peu invasifs pour traiter directement la dilatation du ventricule gauche et inverser le processus de remodelage ventriculaire gauche chez...","og_url":"https:\/\/www.anderapartners.com\/fr\/bioventrix-cloture-un-tour-de-financement-de-serie-a-de-485-millions-de-dollars\/","og_site_name":"ANDERA PARTNERS","article_published_time":"2023-04-13T12:04:45+00:00","article_modified_time":"2023-04-13T12:16:02+00:00","author":"Nicolas Delsert","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Nicolas Delsert","Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.anderapartners.com\/fr\/bioventrix-cloture-un-tour-de-financement-de-serie-a-de-485-millions-de-dollars\/#article","isPartOf":{"@id":"https:\/\/www.anderapartners.com\/fr\/bioventrix-cloture-un-tour-de-financement-de-serie-a-de-485-millions-de-dollars\/"},"author":{"name":"Nicolas Delsert","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c"},"headline":"BioVentrix\u00ae cl\u00f4ture un tour de financement de s\u00e9rie A de 48,5 millions de dollars","datePublished":"2023-04-13T12:04:45+00:00","dateModified":"2023-04-13T12:16:02+00:00","mainEntityOfPage":{"@id":"https:\/\/www.anderapartners.com\/fr\/bioventrix-cloture-un-tour-de-financement-de-serie-a-de-485-millions-de-dollars\/"},"wordCount":439,"publisher":{"@id":"https:\/\/www.anderapartners.com\/fr\/#organization"},"articleSection":["andera Life Sciences"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.anderapartners.com\/fr\/bioventrix-cloture-un-tour-de-financement-de-serie-a-de-485-millions-de-dollars\/","url":"https:\/\/www.anderapartners.com\/fr\/bioventrix-cloture-un-tour-de-financement-de-serie-a-de-485-millions-de-dollars\/","name":"BioVentrix\u00ae cl\u00f4ture un tour de financement de s\u00e9rie A de 48,5 millions de dollars - ANDERA PARTNERS","isPartOf":{"@id":"https:\/\/www.anderapartners.com\/fr\/#website"},"datePublished":"2023-04-13T12:04:45+00:00","dateModified":"2023-04-13T12:16:02+00:00","breadcrumb":{"@id":"https:\/\/www.anderapartners.com\/fr\/bioventrix-cloture-un-tour-de-financement-de-serie-a-de-485-millions-de-dollars\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.anderapartners.com\/fr\/bioventrix-cloture-un-tour-de-financement-de-serie-a-de-485-millions-de-dollars\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.anderapartners.com\/fr\/bioventrix-cloture-un-tour-de-financement-de-serie-a-de-485-millions-de-dollars\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.anderapartners.com\/fr\/"},{"@type":"ListItem","position":2,"name":"BioVentrix\u00ae cl\u00f4ture un tour de financement de s\u00e9rie A de 48,5 millions de dollars"}]},{"@type":"WebSite","@id":"https:\/\/www.anderapartners.com\/fr\/#website","url":"https:\/\/www.anderapartners.com\/fr\/","name":"ANDERA PARTNERS","description":"","publisher":{"@id":"https:\/\/www.anderapartners.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.anderapartners.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.anderapartners.com\/fr\/#organization","name":"Andera Partners","url":"https:\/\/www.anderapartners.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg","contentUrl":"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg","width":107,"height":44,"caption":"Andera Partners"},"image":{"@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c","name":"Nicolas Delsert","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g","caption":"Nicolas Delsert"}}]}},"_links":{"self":[{"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/posts\/23175","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/comments?post=23175"}],"version-history":[{"count":0,"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/posts\/23175\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/media?parent=23175"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/categories?post=23175"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}